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Abstract  Multiparametric  MRI  (mp-MRI)  of  the  prostate  currently  provides  stable  and  repro-
ducible performances.  The  usefulness  of  dynamic  contrast-enhanced  (DCE)  sequences  is
currently  challenged,  as  they  sometimes  only  conﬁrm  what  has  already  been  observed  on
diffusion-weighted  imaging  (DWI)  and  require  the  additional  purchase  of  a  contrast  agent.  Elimi-
nating these  sequences  may  help  accelerate  the  use  of  MRI  in  addition  to,  or  in  lieu  of,  prostate
biopsies  in  selected  patients.  However,  many  studies  show  that  these  sequences  can  detect
lesions invisible  on  T2-weighted  and  diffusion-weighted  images,  better  assess  cancer  extension
and aggressiveness,  and  ﬁnally  help  detecting  recurrence  after  treatment.  We  present  the  var-
ious applications  of  dynamic  MRI  and  discuss  the  possible  consequences  of  its  omission  from  the
current protocol.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Imaging  of  the  prostate  is  often  a  controversial  ﬁeld.  One  subject  under  debate  is  per-
fusion  imaging  (DCE-MRI),  i.e.  T1-weighted  imaging  after  injection  of  a  contrast  agent,  to
locate  intraprostatic  cancer  foci.  The  question  posed  during  the  French  of  Radiology  Day
Conference  2012  is  therefore  topical.
For  about  ﬁve  years,  diffusion  sequences  have  been  incorporated  in  the  standard
prostate  MRI  protocol.  They  have  been  shown  to  improve  detection  of  intraprostatic  tumor
foci  and  often  provide  information  that  is  simply  conﬁrmed  by  the  dynamic  sequences  (loca-
tion  of  a  lesion,  size,  conﬁrmation  of  neoplastic  nature).  This  rapidly  led  to  a  discussion
of  need  for  DCE-MRI  sequences  in  the  standard  imaging  protocol,  despite  numerous  stud-
ies  demonstrating  their  added  value  for  the  detection  and  evaluation  of  lesions  [1—6],  as
in  other  indications  (staging,  detection  of  relapse,  follow-up  of  focal  treatment  etc.),
which  have  not  been  contradicted  to  date.  However,  this  issue  has  rapidly  developed
with  a  proposal  to  only  omit  these  contrast-enhanced  sequences  in  a  single  indication:
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in  the  most  intense  areas  which  are  considered  to  be  those300  
‘tumor  detection’’  MRI,  reserving  contrast-enhanced
equences  for  other  indications  (staging,  detection  of  a  local
ecurrence,  follow-up  during  treatment  etc.).
We  brieﬂy  present  here  the  physiological  basis  of
ontrast-enhanced  MRI  and  its  application  in  prostate  imag-
ng  and  then  discuss  the  usefulness  of  contrast-enhanced
equences  during  prostate  MRI.
ynamic Contrast-Enhanced MRI (DCE-MRI)
rinciples
ost  neoplastic  lesions  greater  than  200  m  induce  neo-
ngiogenesis  which  is  essential  for  their  growth  and
esponsible  for  an  increase  in  the  microvasculature  [7]. This
icrovasculature  mainly  differs  from  that  of  normal  tis-
ue  by  an  increased  permeability  of  the  endothelial  barrier
hat  can  be  demonstrated  by  Dynamic  Contrast-Enhanced
1-weighted  MRI  after  injection  of  gadolinium  (DCE-MRI)
8—12].  This  involves  an  analysis  of  the  signal  measured  as  a
unction  of  time  after  an  intravenous  bolus  injection  of  a  low
olecular  weight  paramagnetic  contrast  agent  (gadolinium
igure 1. Lesion in the peripheral zone that is only detectable by dynam
wo series of biopsies performed 3 (PSA: 4.4 ng/mL) and 4 years previous
efore the 3rd series of biopsies, showed a nodular lesion of 13 mm in l
obe of the prostate gland (yellow target on the ﬁve sequences: a) T2
ap (b = 0—600), e) contrast-enhanced T1-weighted sequence at the 6 e
ynamic contrast-enhanced series (e), appearing at the ﬁfth time of the
DC map (d). It was barely visible on the DWI with b = 600. After prostate
 + 3 = 7 with 70% grade 4 and focal extraprostatic extension.
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helate)  that  freely  diffuses  into  the  EES  (Extravascular
xtracellular  Space)  with  a  rate  that  increases  with  the
mpairment  in  the  integrity  of  the  endothelial  barrier.  The
rst  phase  of  enhancement  called  ‘‘wash-in’’  or  ‘‘ﬁlling’’
s  observed  when  the  contrast  agent  ﬁlls  the  vascular  com-
artment  and  rapidly  diffuses  into  the  EES  [13].  This  is  a
ood  reﬂection  of  the  microvessel  density  in  the  region  of
nterest.  When  enhancement  has  reached  its  peak  inten-
ity  and  there  is  an  equilibrium  concentration  between  the
ascular  compartment  and  the  EES,  the  contrast  returns
o  the  vascular  compartment  as  its  intravascular  concen-
ration  decreases  after  passage  of  the  bolus.  A  second
limination  phase,  called  ‘‘wash-out’’  begins,  reﬂecting  the
isplacement  of  contrast  agent  in  the  opposite  direction
rom  the  EES  into  the  vascular  compartment.  The  wash-out
ate  increases  with  damage  to  the  endothelial  barrier.  These
henomenons  can  be  studied  in  three  different  ways:
by  direct  examination  of  images  and  looking  on  the
dynamic  series  for  areas  where  the  contrast  appears  ﬁrstic sequences. 59-year-old patient with elevated PSA of 6.5 ng/mL.
ly (PSA: 3.7 ng/mL) were negative. Multiparametric MRI performed
ongest diameter in the middle and basal areas of the right lateral
 TSE axial image, b) DWI with b = 0, c) DWI  with b = 600, d) ADC
arliest times without subtraction. The lesion is only visible on the
 injection. It was not detectable on the T2-WI sequence (a) or the
ctomy, this was found to be a pT3aNxR0 cancer of 15 mm, Gleason
where  the  wash-in  is  the  most  important  (Figs.  1—3);
using  the  contrast  agent  time/intensity  curve  in  a  region
of  interest  so  that  the  reading  permits  an  assessment
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Figure 2. Lesion of the peripheral zone only detectable on contrast-enhanced sequences. 70-year-old patient with elevated PSA of
5.6 ng/mL and right induration during DRE. MRI performed before a second series of biopsies, as the ﬁrst series had diagnosed a microfocus
of 2 mm on the right. Given the discrepancy between the biopsies and the DRE, the urologist requested an MRI. a) axial T2 TSE image, b) ADC
map (b = 0—600), c) dynamic, contrast-enhanced T1-weighted imaging at the 6 earliest times without subtraction, d) dynamic, contrast-
enhanced T1-weighted imaging at the 6 earliest times with subtraction. The examination showed a prostate with multiple abnormalities on
T2-WI (a). The diffusion sequence (b) showed no lesion. It was very difﬁcult to read due to an artifact associated with intrarectal air. The
perfusion sequence (c and d) clearly showed a nodular contrast enhancement of 10 mm in longest diameter in the mid region of the right
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Llateral lobe with no direct evidence of extraprostatic extension. T
Directed biopsy established its neoplastic nature with Gleason grad
of  the  wash-out  phenomenon:  rapid,  plateau,  or  absent
during  the  acquisition  time  (usually  5  minutes  to  study
it  properly)  [14].  These  curves  may  be  studied  on  a
computer  to  obtain  ‘‘semi-quantitative’’  values:  wash-
in/wash-out  rates  per  second;  peak  amplitude;  relative
enhancement,  time  to  peak,  area  under  the  curve  of  the
ﬁrst  90  seconds  etc.  [15];
• ‘‘quantitative’’  values  are  then  obtained  by  trying  to
ﬁt  the  measured  signal  to  a  theoretical  signal  with  a
mathematical  formula  incorporating  a  permeability  fac-
tor  between  two  or  more  compartments  such  as  the  Tofts,
extended  Tofts  or  Brix  models  etc.  The  most  well  known
parameters  are  K-trans  (endothelial  barrier  permeabil-
ity  coefﬁcient),  Ve  (extravascular—extracellular  volume
fraction)  and  Vp  (plasma  volume).  These  ‘‘quantitative’’
calculations  require  the  integration  of  many  technical
constraints,  including  in  particular  the  transformation  of
the  absolute  signal  measured  by  the  gadolinium  concen-
tration  in  the  region  of  interest  and  taking  into  account
the  arterial  input  function  of  the  organ  which  is  very  dif-
ﬁcult  to  estimate  accurately.Application to prostate cancer
Prostate  tumors  are  hypervascularized  [16].  Moreover  it  has
been  shown  that  the  microvessel  density  is  a  prognostic
I
s
page was best seen on the reconstructed series with subtraction.
3 = 6, as did prostatectomy (pT2N0MxR0).
actor  independent  of  stage  and  probably  of  tumor  aggres-
iveness  [17]  and  subsequently  that  MRI  is  able  to  quantify
he  microvessel  density  [18]  and,  therefore,  these  progno-
tic  factors.  In  theory,  prostate  cancers  therefore  present
ore  rapid  wash-in  and  wash-out  phases  than  healthy  zones
ut  there  are  many  false  positives  (inﬂammatory  tissue,
bromuscular  component  of  BPH  [Benign  Prostatic  Hyperpla-
ia],  stromal  nodules)  and  false  negatives  (cancers  with  low
nhancement).  The  main  task  of  the  radiologist  is  therefore
o  distinguish  areas  where  enhancements  can  be  considered
uspicious  for  cancer.  For  this,  certain  ﬁndings  are  more
seful  than  others.  A  recent  study  based  on  the  analysis
f  53  prostatectomy  specimens  showed  that  the  maximum
oncentration  peak  and  wash-in  parameters  were  constantly
ncreased  in  case  of  cancer  and  that  a combination  of  wash-
n  and  wash-out  alone  gave  the  best  diagnostic  accuracy,
easured  with  an  area  under  the  ROC  curve  of  0.86  [19].
linical applications
esion detectiont  is  now  nearly  20  years  since  dynamic  contrast-enhanced
equences  were  ﬁrst  described  for  the  investigation  of  the
rostate.  Their  added  value  in  purely  ‘‘morphological’’
1302  P.  Puech  et  al.
Figure 3. Aggressive transition zone lesion only detectable on contrast-enhanced images and undetectable by DWI. This 63-year-old
patient had an elevated PSA of 6.61 ng/mL versus 3.64 ng/mL 3 years previously. DRE ﬁrm on the right. MRI performed before a ﬁrst series
of biopsies. a) axial T2 TSE image, b) DWI with b = 0 (left) and b = 600 (right), c) ADC map (b = 0—600), d) dynamic contrast-enhanced, T1-
weighted sequence at the 6 earliest times without subtraction. A hypervascular lesion in the anterior, right and middle part of the gland was
detected on the dynamic sequence (d). It measured approximately 16 mm and showed no direct evidence of extracapsular extension. It was
only visible retrospectively on T2-weighted images (a) and was not detectable on the diffusion-weighted images (b and c). One systematic
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uiopsy was positive (3 mm Gleason 3 + 3 = 6) in the right mid lateral
 + 3 = 7 and 3 + 5 = 8).
maging  protocols  including  only  T2-weighted  sequences
as  been  repeatedly  demonstrated  [18,20—31], though  this
as  also  been  shown  for  protocols  including  combined  T2-
eighted  imaging  (T2-WI)  and  diffusion-weighted  imaging
DWI)  [1,32—37]  and  T2-WI,  DWI  and  spectroscopy  [38],
hether  the  images  were  interpreted  on  the  console,  or
sing  a  Computer  Assisted  Design  (CAD)  system  [39,40].
In  general,  these  studies  have  shown  that  DCE-MRI
mproves  the  sensitivity  of  detection  of  lesions  by  about
0  to  15%,  with  no  signiﬁcant  decrease  in  speciﬁcity
1—6,35—37].  The  study  of  Kozlowski  et  al.  (on  32  tumors),
howed  that  the  sensitivity  in  detecting  lesions  improved
rom  54%  to  87%  (+33%)  when  diffusion  and  perfusion
equences  were  combined  [32].  The  study  by  Tanimoto  et  al.
f  88  prostatectomy  specimens  showed  an  improvement  in
etection  sensitivity  from  84  to  95%  (+11%)  and  in  accuracy
rom  an  area  under  the  ROC  curve  of  0.905  to  0.966  (P  <  0.01)
y  using  the  same  combination  [1].
This  gain  is  all  the  greater  for  anterior  lesions  that  are
idden  in  a  transition  zone  that  naturally  consists  of  areas
f  myomatous,  ﬁbrous  or  calciﬁed  tissue  with  a  low  T2  and
iffusion  signal  (Fig.  3).  MRI  can  detect  those  hypervascu-
ar  lesions  that  asymmetrically  alter  the  structure  of  the
denoma  or  are  localized  in  speciﬁc  areas  (anterior  ﬁbro-
uscular  stroma,  anterior  part  of  the  gland).  Lesions  of  the
nterior  ﬁbromuscular  stroma,  which  are  usually  hidden  in  a
o
i
i
cn, but four biopsies were positive between 1 and 11 mm (Gleason
brous  tissue  (hypo-intense  signal  on  T2-WI  and  DWI  and  on
he  ADC  map),  are  easily  detectable  on  dynamic  sequences.
n  the  peripheral  zone,  DCE  sequences  are  mainly  effective
n  detecting  non-nodular,  inﬁltrating  vascular  lesions,  which
re  poorly  visible  on  T2-WI  or  DWI  [41]  (Figs.  1  and  2).
valuation of aggressiveness of lesions
everal  studies  have  highlighted  the  relationship  between
ynamic  imaging  parameters  and  certain  markers  of  the
ggressiveness  of  prostate  lesions:  microvessel  tissue  den-
ity  [42],  Gleason  score  [43,44].  At  macroscopic  level,
xtracapsular  (extraprostatic)  extension  and  seminal  vesicle
nvasion  are  other  ﬁndings  demonstrating  the  aggressiveness
f  lesions  that  we  will  describe  separately.
xtracapsular extension
he  accuracy  of  morphological  MRI  to  evaluate  the  extra-
apsular  extension  of  a  lesion  is  very  variable  and  mainly
epends  on  the  experience  of  readers  and  the  semiotics
sed,  with  a  sensitivity  of  about  33—50%,  but  a speciﬁcity
f  more  than  80%  in  most  studies  [45—50].  Sensitivity  is
ncreased  by  the  injection  of  contrast  material  that  can
mprove  the  visibility  of  direct  signs  of  extension,  by  showing
ontrast  enhancement  beyond  the  prostate  surface  or  in  the
I
v
i
l
d
t
P
t
P
i
s
e
w
D
R
f
h
s
a
tumor  recurrence  which  in  most  cases  will  be  hypervas-Prostate  MRI:  Can  we  do  without  DCE  sequences  in  2013?  
periprostatic  fat  [51].  This  contrast  enhancement  may,  how-
ever,  be  linked  to  other  processes  (inﬂammatory)  and  cause
false  positives,  probably  explaining  the  discordant  results
described  in  the  literature  on  this  subject  [20,52—57],
although  only  a  few  speciﬁc  studies  are  available.
Seminal vesicle invasion
The  MRI  evaluation  of  the  seminal  vesicles  is  facilitated  by
contrast-enhanced  sequences  that  improve  their  visualiza-
tion  and  study  in  approximately  23%  of  cases,  especially
for  inexperienced  readers  [24].  As  for  direct  extraprostatic
extension,  these  results  are  debatable  in  certain  series
[57,58].  Evidence  for  seminal  vesicle  invasion  is  based  on
two  signs,  whose  reliability  is  even  better  when  combined
[59]:  ﬁlling  of  the  seminal  lumen  and  presence  of  asym-
metrical  or  nodular  seminal  enhancement  (Fig.  4).  Unlike
direct  extraprostatic  extension,  the  evaluation  of  seminal
vesicle  invasion  is  of  great  importance  as  its  presence  is
directly  correlated  with  prognosis  and  may  lead  to  a  change
in  treatment  [60,61].Detection of recurrence after prostatectomy
PSA  rising  after  prostatectomy  (theoretically  zero  three
months  after  surgery)  is  a  marker  of  biochemical  recurrence.
c
c
o
i
Figure 4. Value of the injection of contrast for the detection of initia
of 35 ng/mL. MRI performed before a ﬁrst series of biopsies, also showi
aggressive lesion Gleason 4 + 3 = 7), for which an evaluation of seminal ves
part of the vesicles, b) DWI with b = 0 (left) and b = 600 (right), c) ADC ma
at 6 earliest times, without subtraction. The dynamic sequence (d) show
(white arrow), which was not detectable on the T2 sequence (a), where t
abnormality on DWI, which is usually unhelpful in this indication due to 1303
n  most  cases,  surgeons  wait  until  this  PSA  reaches  a  certain
alue  (0.2  ng/mL  on  two  consecutive  assays)  before  declar-
ng  the  recurrence  and  the  question  is  then  raised  about  its
ocation  and  the  need  for  additional  treatment.  This  will  be
ifferent  whether  the  recurrence  is  localized  in  the  prosta-
ectomy  bed,  or  if  patient  has  lymph  nodes  or  metastases.
elvic  MRI  is  increasingly  requested  to  assess  the  prostatec-
omy  bed  because  it  is  currently  more  effective  than  choline
ET  when  the  PSA  is  low  (<1  ng/mL)  and  effective  therapy
s  still  possible.  Several  studies  have  shown  that  DCE-MRI
equences  are  particularly  useful  for  the  detection  of  recurr-
nces  as  [62—64], in  most  cases,  they  lead  to  enhancement
ithin  the  scar  tissue.
etection of recurrence after radiotherapy
adiation  induces  changes  in  prostate  tissue  (atrophy,  dif-
use  reduction  in  T2-  and  diffusion-weighted  signal)  that
inder  the  detection  of  recurrences  on  morphological
equences.  Fibrosis  and  the  decreased  microvasculature  of
trophic  tissue  will  increase  the  contrast  of  a  potentialularized  like  the  initial  lesion.  This  makes  the  dynamic
ontrast-enhanced  series  a  key  element  in  the  detection
f  recurrences,  and  MRI  an  excellent  examination  for  this
ndication  [65—69].
l seminal vesicle invasion. 66-year-old patient with elevated PSA
ng a large lesion of the middle basal region (later found to be an
icle invasion is paramount. a) T2 TSE axial image through the lower
p, b = 0—600, d) dynamic contrast-enhanced T1-weighted sequence
ed early nodular contrast enhancement in the right seminal vesicle
he vesicles appeared perfectly symmetric. There was no signiﬁcant
its low spatial resolution, frequent artifacts and noise.
1M
N
a
l
i
f
m
D
v
a
e
c
a
W
P
T
i
•
•
•
•
b
r
p
m
r
j
c
c
c
t
c
c
o
d
C
a
h
a
W
c
t
e
‘
M
a
a
w
p
b
p
w
p
c
•
•
•
o
f
e
w
f
b
m
t
o
m
a
m
m
a
o
m
e
r
C
D
M304  
onitoring of focal treatments
ew  therapeutic  options  for  prostate  cancer  (cryother-
py,  vascular  phototherapy,  hi-intensity  focused  ultrasound,
aser  thermotherapy,  etc.)  usually  require  early  monitor-
ng  of  their  efﬁcacy  (after  8  days  in  most  protocols)  and
ollow-up  during  time  to  detect  any  recurrence  after  treat-
ent  [52,70].  In  these  two  cases,  alterations  on  T2-WI  and
WI  sequences  are  not  speciﬁc,  whereas  dynamic  imaging  is
ery  informative:  it  shows  hypovascular  or  necrotic  areas,
nd  allows  the  description  of  their  topography,  volume,  and
xtension.  Recurrences  take  the  form  of  plaques  of  local
ontrast  enhancement  in  the  treated  area  or  at  its  periphery,
s  seen  after  radiotherapy.
hy omit contrast-enhanced sequences?
lea  for a ‘‘standardized’’ protocol
he  omission  of  sequences  with  injection  of  a  contrast  agent
s  currently  supported  by  four  arguments:
they  do  not  provide  a  signiﬁcant  diagnostic  gain  and  are
therefore  useless;
they  generate  unjustiﬁed  extra  costs  by  making  patients
purchase  a  gadolinium-based  contrast  agent;
the  risks  associated  with  the  injection  of  this  contrast
agent  are  not  justiﬁed;
they increase  the  duration  of  the  examination  and  make
it  less  accessible.
However,  this  question  has  only  really  been  raised
ecause  of  the  growing  willingness  of  the  urological  and
adiological  communities  to  use  MRI  more  broadly  as  a  com-
lement  to  prostate  biopsy,  for  the  beneﬁt  of  patients  who
ore  easily  accept  screening  (no  endorectal  insertion,  pain,
ectal  bleeding,  risk  of  infection  etc.).  For  this,  we  must
ustify  the  medical  economic  beneﬁt,  as  although  there  is  a
lear  medical  beneﬁt  [71,72]  (Figs.  2  and  3),  the  additional
ost  of  including  MRI  in  the  standard  individual  prostate  can-
er  screening  program  remains  open  to  question.  We  must
herefore  ﬁnd  new  savings.
We  have  already  discussed  the  signiﬁcant  contribution  of
ontrast-enhanced  sequences  to  the  detection,  localization,
haracterization,  assessment  of  aggressiveness  and  staging
f  prostate  lesions  and  we  will  not  mention  the  increased
uration  of  the  examination  which  is  negligible  (5  minutes).
oncerning  the  ‘‘risk’’  of  the  injection  for  patients,  it  may
lso  be  considered  very  low,  as  systemic  nephrogenic  ﬁbrosis
as  become  very  rare  since  certain  precautionary  measures
re  taken  and  hypersensitivity  reactions  are  rare  [73—75].
e  can  therefore  reassure  patients  about  this.
The  question  of  the  additional  cost  is,  however  more
oncerning,  because  the  cost  of  contrast  agents  is  rela-
ively  high  (about  80D,  20  to  30%  of  the  total  cost  of  the
xam)  and  hampers  the  possibility  of  reimbursing  the  whole
‘screened’’  population,  and  consequently  the  indication  of
RI  for  individual  detection.  We  will  not  enter  into  a  debate
bout  a  comparison  of  the  cost  of  DCE-MRI  with  that  of  MRI few  years  ago  (with  endorectal  coil,  longer  exams  etc,  or
ith  the  new  laboratory  techniques  that  are  already  widely
rescribed  and  much  more  expensive  for  a  controversial
eneﬁt  (PCA3).  If  this  MRI  screening  is  applied  to  the  same
e
b
l
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opulation  that  currently  undergoing  transrectal  biopsies,
e  can  relativize  the  additional  cost  of  contrast  products  by
ointing  out  the  potential  savings  that  can  made  by  including
ontrast-enhanced  sequences:
reduction  in  the  number  of  unnecessary  biopsy  series
after  obtaining  a more  accurate  diagnosis  with  optimal
negative  predictive  value  as  the  injection  of  contrast
improves  the  detectability  of  lesions  and  diagnostic  accu-
racy.  How  could  the  idea  of  a  better  quality  examination
than  biopsies  to  detect  signiﬁcant  cancer  and  exclude
non-signiﬁcant  cancer,  be  defended  without  providing  the
means  to  obtain  an  optimum  performance  [1,6]?  This
might  unnecessarily  discredit  MRI  with  urologists  and
patients  and  could  be  considered  a  backward  step;
a  reduction  in  biopsy  series  during  active  surveillance,  for
the  same  reasons;
the  possibility  of  performing  the  whole  preoperative
assessment  in  a single  session  without  repeating  the
examination  if  there  really  is  a  cancer  at  the  end  of  this
detection  stage  (staging  requires  a  second  MRI  to  assess
‘‘extension’’).  The  relevance  of  a  two-stage  imaging  eval-
uation,  may  be  asked  with  respect  to  the  actual  beneﬁt
for  urologists  and  radiotherapists  during  the  diagnosis
disclosure  visit,  as  they  may  not  being  able  to  propose
a  clear  approach  to  their  patients,  due  to  suboptimal
information  (number  of  lesions,  presence  of  other  lesions
modifying  the  therapeutic  approach,  and  extracapsular
extension  and  seminal  vesicle  invasion).  The  same  is  true
for  patients,  some  of  whom  may,  by  own  their  will  or  that
of  the  therapist,  not  beneﬁt  from  a  more  comprehensive
assessment  to  further  accelerate  their  management.  This
would  again  be  a  probably  damaging  backward  step.
Standardization  of  protocols  is  one  of  the  main  strengths
f  prostate  imaging  at  present.  It  is  currently  possible  to  per-
orm  a  work-up  to  detect  lesions  and  staging  during  a  single
xamination  under  optimum  conditions.  The  currently  most
idely  used  multiparametric  protocol  (T2,  diffusion,  per-
usion)  facilitates  the  implementation  of  the  examination
y  teams  of  varying  experience  by  harmonizing  their  perfor-
ance  and  quality  of  service,  increases  the  accessibility  of
he  examination,  the  power  of  multicenter  studies,  the  trust
f  urologists  and  patients  by  providing  a  reproducible  assess-
ent  of  their  disease.  The  omission  of  DCE  sequences  within
 brand  new  speciﬁc  indication  (called  ‘‘detection’’  MRI)
ust  be  rigorously  analyzed  before  being  proposed  as  the
edical  risk  may  outweigh  the  supposed  savings,  especially
s  this  diagnostic  pathway  would  involve  the  performance
f  another  complementary  MRI  if  cancer  is  established  and
ay,  in  case  of  sub-optimal  performance,  lead  to  the  rep-
tition  of  the  examination  and  its  discredit,  reducing  its
eadability  (multiplication  and  complexity  of  protocols).
onclusion
CE-MRI  is  one  of  the  cornerstones  of  the  multiparametric
RI  of  the  prostate.  Its  value  to  improve  the  detection  and
valuation  of  the  aggressiveness  of  the  cancer  has  never
een  questioned  in  the  literature  simply  because  it  high-
ights  different  histological  features  from  those  observed  by
2-WI  or  DWI.  It  is  also  essential  in  the  multiple  indications
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occurring  during  the  management  of  prostate  cancer  by
imaging  (detection  of  recurrences,  staging,  follow-up  of
focused  therapies  etc.).
TAKE-HOME  MESSAGES
• Multiparametric  MRI  of  the  prostate  comprises
complementary  and  synergistic  T2,  diffusion  and
perfusion  sequences.
• Contrast-enhanced  sequences  signiﬁcantly  improve
the  accuracy  of  the  examination  for  the  detection
and  evaluation  of  intraprostatic  tumor  lesions.
• Omitting  them  increases  the  risk  of  not  detecting
some  aggressive  lesions  and  therefore  discrediting
prostate  imaging  by  MRI.
• Contrast-enhanced  sequences  are  essential  in  the
following  indications:  detection  of  recurrences  and
follow-up  after  treatment.
Clinical case
This  66-year-old  patient  had  an  elevated  PSA  of  4.59  ng/mL
versus  4.11  ng/mL  1  year  previously.  There  were  mild  urinary
functional  signs.  No  history  of  urinary  tract  infection.  The
digital  rectal  examination  found  a  soft  prostate.  MRI  was
performed  before  the  ﬁrst  series  of  prostate  biopsies.  You
do  not  know  if  the  patient  has  cancer  or  not.  Here  is  an
image  of  a  prostate  axial  section  (Fig.  5).
Questions
1)  How  would  you  describe  the  images  (use  the  Pi-RADS
score  if  possible)?
2)  Do  you  think  this  image  is  suspicious?
3)  Why  is  this  lesion  not  visible  (or  barely)  on  the  T2-WI  and
DWI  sequences?
Response
1)  According  to  the  ESUR  2012  guidelines,  describing  the
ﬁrst  version  of  the  Pi-RADS  score  [75],  the  lesion  is
located  in  the  mid  portion  of  the  right  lateral  lobe  (area
04p)  (Fig.  6)  [76,77],  measures  about  20  mm  and  has
a  Pi-RADS  score  of  6  or  7  out  of  15  points;  scored  2
points  on  the  T2-WI  (‘‘poorly-deﬁned  hypo-intense  T21305
area’’)  +  1  point  by  DWI  (‘‘no  signal  reduction  in  ADC
or  increase  in  imaging  with  b-value  >  800’’)  +  3  points
by  DCE  (‘‘type  3  enhancement  —  3 points  with  focal
appearance  —  +  point’’).  Type  2  enhancement  is  possible
(2  points),  as  the  wash-out  phenomenon  is  poor.  The  like-
lihood  of  extraprostatic  tumor  invasion  is  low  (1  in  5),  as
there  is  no  anomaly  or  irregularity  of  the  prostate  sur-
face.  Note  the  progressive  enhancement  (type  1)  of  the
contralateral  healthy  prostate.
)  Despite  the  relatively  indecisive  nature  of  the  Pi-
RADS  ‘‘objective’’  score,  we  can  give  the  lesion  a
‘‘subjective’’  score  of  5  out  of  5  (Fig.  7),  as  the  contrast
enhancement  is  very  suspicious,  asymmetrical,  nodular
and  focal.  There  is  no  upper  limit  for  the  Pi-RADS  score,
which  describes  the  sequences.  Its  prospective  clinical
validation  is  in  progress.  If  the  patient  had  a  past  his-
tory  of  urinary  tract  infection  or  clear  functional  signs  a
score  of  4  out  of  5  could  be  considered  as  a  hypotheti-
cal  focus  of  prostatitis  could  not  be  ruled  out.  Prostate
biopsies  showed  two  positive  cores  in  the  mid  lateral  and
mid  regions  of  the  right  lobe  (4  and  8  mm  Gleason  ade-
nocarcinoma  3  +  4  =  7  on  two  cores  of  12  mm  each).  The
guided  biopsies  were  also  positive  and  also  showed  per-
ineural  extension.  All  the  other  biopsies  (10  cores  out  of
14)  were  negative.
)  Prostate  tumor  lesions  have  variable  histological  char-
acteristics  (degree  of  inﬁltration  of  the  stroma,
homogeneity,  microvasculature,  cell  density,  architec-
ture,  histological  grade  etc.)  which  are  not  always
homogeneously  visible  on  all  sequences.  Rosenkrantz
et  al.  recently  demonstrated  that  lesions  visible  on
diffusion-weighted  images  were  those  that  were  hard  to
see  on  DCE  images  and  vice  versa.  In  general,  lesions
visible  on  T2-WI  are  also  detectable  on  DWI,  but  their
behaviour  on  DCE  series  is  variable.  Certain  lesions  are
visible  on  T2-WI  and  DWI  but  not  on  dynamic  series
whereas,  on  the  contrary,  others  that  are  only  visible
on  the  dynamic  series,  are  almost  invisible  on  non-
contrast-enhanced  sequences.  The  visibility  of  lesions
also  depends  on  the  contrast  with  the  surrounding  tissue.
When  the  prostate  has  a low  T2  (chronic  inﬂammation
etc.),  nodules  are  less  contrasted  and  more  difﬁcult
to  detect.  This  case  illustrates  the  importance  of  per-
fusion  sequences  for  the  detection  of  prostate  lesions,
particularly  in  the  peripheral  zone,  and  shows  that
diffusion-weighted  imaging  may  not  detect  lesions  of  sig-
niﬁcant  size  and  aggressiveness  (Gleason  3  +  4  =  7  on  4
biopsies).
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Figure 5. a) T2-weighted axial image. b) Diffusion-weighted axial image obtained with gradient b = 600, same slice. c) Diffusion-weighted
axial image obtained with diffusion gradient b = 1000, same slice. d) Reconstructed ADC image with b = 0—600, same slice. e) Non-contrast-
enhanced T1-weighted image; same slice. f) Dynamic contrast-enhanced T1-weighted image on the second series where the contrast is
v n red
o
isible; same slice. g) Enhancement curves obtained on this slice; i
n the contralateral peripheral zone. on the lesion in the hypervascular right peripheral zone; in green,
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Figure 7. Evaluation of prostate lesions according to a score of from 1 to 5 (78). a) Nodular lesion of transition zone which is non-suspicious
(1/5) despite its high vascularity due to a ‘‘ringed’’ appearance of the nodule by T2-WI and the absence of signal loss on the ADC map.
Negative biopsies. b) Highly suspicious lesion (4/5) of left transition zone, because of its anterior location, homogeneous and asymmetric
appearance relative to the rest of the adenoma by T2-WI and vascularity and despite the low restricted diffusion. If the diffusion image had
been consistent, a score of 5/5 would be logical. Cancer conﬁrmed by prostatectomy. c) Equivocal lesion (3/5) of the left peripheral zone,
despite its isolated position in the peripheral zone, making it similar to the lesion visible in d). The hypo-intense T2 signal is unclear and
not nodular; restriction of diffusion is low and contrast uptake is unpronounced with respect to the rest of the parenchyma. These ﬁndings
are discordant. Finally, the perfusion and T2 sequences showed that this was a ‘‘low suspicion’’ lesion, so no decision could be made and it
was deemed ‘‘equivocal’’. Prostatectomy conﬁrmed the benign nature of this image. d) Very highly suspicious lesion of the left peripheral
zone (5/5) due to its isolated nature in a normal peripheral zone, its nodular form and the deep and homogeneous hypo-intense signal on
T
t
2-weighted images. The restriction of diffusion and contrast enhanceme
end to impose a score 5/5 instead of 4/5. Lesion demonstrated by prosnt is pronounced and nodular. All these ﬁndings are consistent and
tatectomy.
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